Activity Overview
Endocrine therapy remains the cornerstone of management for patients with early-stage, hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) breast cancer. For patients at higher risk of recurrence, additional treatment can offer benefit in terms of prolonged disease control and survival. As the number of available treatment options continues to grow, selecting the right therapy for the right patient has become increasingly complex.
This program brings together experts in the management of HR+ breast cancer to discuss best practices for identifying patients who are most in need of additional adjuvant treatment. Discussions focus on the role of targeted agents in the adjuvant setting, as well as the potential use of novel endocrine approaches and immunotherapy. These discussions are presented in the Medical Crossfire® format, designed to present challenging decision points for the faculty to consider and debate.
This educational activity is an archive of the live virtual symposium held at the 43rd Annual Miami Breast Cancer Conference® on March 5, 2026.
Target Audience
This educational activity is directed toward medical oncologists, surgical oncologists, radiation oncologists, oncology nurses, advanced practice professionals, pathologists, and other health care practitioners who manage patients with breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate clinical evidence supporting the use of current and emerging therapies in the adjuvant treatment of HR+/HER2– early breast cancer
- Design individualized treatment strategies that incorporate genomic profiling and clinicopathologic risk factors to optimize outcomes in patients with early-stage HR+/HER2– breast cancer
- Implement best practices to support adherence and tolerability, including shared decision-making, patient education, and proactive management of treatment-related toxicities for early-stage HR+/HER2– breast cancer
Ann H. Partridge, MD, MPH
Professor
of Medicine
Harvard
Medical School
Eric P.
Winer, MD, Chair in Breast Cancer Research
Vice
Chair, Department of Medical Oncology
Co-founder
and Director, Program for Young Adults with Breast Cancer
Dana-Farber
Cancer Institute
Boston,
MA
Disclosures: Ann H. Partridge, MD, MPH, has no relevant financial relationships with ineligible companies.
William J. Gradishar, MD, FASCO, FACP
Betsy
Bramsen Professor of Breast Oncology and Professor of Medicine
Chief,
Division of Hematology/Oncology
Feinberg
School of Medicine at Northwestern University
Chicago,
IL
Disclosures: Co-Investigator: Gilead, Menarini Group, Pfizer; Data Monitoring Committee: Lilly, Menarini Group
Saranya Chumsri, MD
Oncologist
Division
of Hematology and Medical Oncology
Mayo
Clinic
Jacksonville,
FL
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca, Biotheranostics, Daiichi Sankyo, Eisai, Genentech, Menarini Stemline, Novartis, Pfizer, Puma Biotechnology, Seagen; Grant/Research Funding: BriaCell Therapeutics, Merck & Co, Novartis, Pfizer, Salix Pharmaceuticals
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here